Liquid biopsy testing in the diagnosis of lung cancer

QuicDNA - Integration of Liquid Biopsy into Lung Cancer Diagnostic

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN22734699

Enrollment

1260

Registered

2023-06-19

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with suspected stage III (excluding radical treatment) and IV lung cancer based on computer tomography (CT scan) and have tissue biopsy (SOC) diagnostic testing planned Cancer

Interventions

Patients will be identified by an NHS Respiratory Consultants (RC) at Health Boards and given a copy of the PIS. If the patient is interested in participating, their details will be passed to the Rese

Eligibility

Sex/Gender

All

Age

16 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Be willing and able to provide written informed consent for the study 2. Age 16 years or over on day of signing informed consent 3. Have radiologically suspected advanced stage III (excluding radical treatment) and stage IV lung cancer from CT scan as evaluated and reported by clinical team and/or a radiologist 4. Consent to have a genetic analysis performed on ctDNA from their blood sample 5. Have a performance status of 0 or 3 on the ECOG Performance Scale

Exclusion criteria

Exclusion criteria: 1. Is unable or unwilling to comply with study procedures 2. Stage I, II, or III suspected lung cancer that qualifies for radical treatment (surgery, radical radiotherapy or chemoradiotherapy) 3. Have any known concurrent malignancy

Design outcomes

Primary

Measure	Time frame
Measured using patient records at the end of the study: 1. Time from participant’s first appointment at the Rapid Access Clinic to start of treatment allocation in the two cohorts of comparison (liquid biopsy testing vs. tissue SoC tissue biopsy testing) at an early stage in the lung cancer diagnostic pathway 2. Patients’ allocation to treatment in the two cohorts of test (liquid biopsy testing vs. tissue SoC tissue biopsy testing) in the lung cancer diagnostic pathway	—

Measure

Time frame

Measured using patient records at the end of the study: 1. Time from participant’s first appointment at the Rapid Access Clinic to start of treatment allocation in the two cohorts of comparison (liquid biopsy testing vs. tissue SoC tissue biopsy testing) at an early stage in the lung cancer diagnostic pathway 2. Patients’ allocation to treatment in the two cohorts of test (liquid biopsy testing vs. tissue SoC tissue biopsy testing) in the lung cancer diagnostic pathway

—

Secondary

Measure	Time frame
Measured using patient records at the end of the study: 1. Time from sample collection to genomic report in the two cohorts of comparison (liquid biopsy vs. SoC tissue biopsy) 2. Time from suspected diagnosis of lung cancer on CT scan until the first day of treatment 3. Detection of actionable variants by NGS ctDNA panel compared to the SOC tissue diagnostic testing 4. Failure to detect actionable variants by NGS ctDNA panel compared to the SOC tissue diagnostic testing 5. Patients’ response to treatment (RT), Progression-free survival (PFS) and Overall Survival (OS) in the two cohorts of comparison 6. Number of prevented repeat tissue biopsies in the ctDNA cohort compared to the SoC tissue cohort	—

Measure

Time frame

Measured using patient records at the end of the study: 1. Time from sample collection to genomic report in the two cohorts of comparison (liquid biopsy vs. SoC tissue biopsy) 2. Time from suspected diagnosis of lung cancer on CT scan until the first day of treatment 3. Detection of actionable variants by NGS ctDNA panel compared to the SOC tissue diagnostic testing 4. Failure to detect actionable variants by NGS ctDNA panel compared to the SOC tissue diagnostic testing 5. Patients’ response to treatment (RT), Progression-free survival (PFS) and Overall Survival (OS) in the two cohorts of comparison 6. Number of prevented repeat tissue biopsies in the ctDNA cohort compared to the SoC tissue cohort

—

Countries

United Kingdom, Wales

Contacts

Public ContactGeorgina Gardner

quicdna@cardiff.ac.ukNone available

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026